Arcutis Biotherapeutics (ARQT), announced that the U.S. Food and Drug Administrathas approved the supplemental new drug application for ZORYVE cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age. Once-daily ZORYVE cream 0.05% provides rapid and significant clearance of atopic dermatitis anywhere on the body and offers clinicians, parents, and caregivers of children ages 2 to 5 an alternative to steroids that can be used for any duration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics announces new Zoryve data at EADV congress
- Arcutis Biotherapeutics sybmits sNDA for ZORYVE Cream 0.3%
- Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges
- Arcutis Biotherapeutics price target raised to $25 from $20 at TD Cowen
- Arcutis Biotherapeutics: Promising Growth Driven by Zoryve’s Success and Strategic Initiatives